Cimzia vs Skyrizi for Crohn's Disease: Comparing Options

Cimzia and Skyrizi represent two different generations of biologic therapy for moderate-to-severe Crohn's disease. Cimzia (certolizumab pegol) is a subcutaneous anti-TNF biologic that has been a Crohn's option since 2008. Skyrizi (risankizumab) is an IL-23 p19-selective biologic approved for Crohn's in June 2022 based on the ADVANCE, MOTIVATE, and FORTIFY trials. Patients comparing these drugs weigh established anti-TNF mechanism against a newer class with strong efficacy and safety data. This guide walks through the cimzia vs skyrizi crohn's comparison.

Anti-TNF vs IL-23 p19 Mechanism

Cimzia binds TNF-alpha, a cytokine that drives inflammation throughout the body and in the gut. Skyrizi binds the p19 subunit of interleukin-23, selectively blocking IL-23 signaling while preserving IL-12. IL-23 is a central driver of Th17-mediated inflammation in Crohn's. The certolizumab vs risankizumab distinction shapes both speed of onset and the long-term safety profile. Cimzia's broader TNF blockade produces rapid systemic anti-inflammatory effects. Skyrizi's selective IL-23 inhibition produces strong efficacy with a cleaner infection profile.

Efficacy in Crohn's

Cimzia's Crohn's efficacy rests on PRECISE-1 and PRECISE-2, which showed significant clinical response and remission benefits over placebo. Skyrizi's Crohn's efficacy rests on ADVANCE and MOTIVATE (induction) and FORTIFY (maintenance). ADVANCE enrolled biologic-naive and biologic-experienced Crohn's patients. Both ADVANCE and MOTIVATE showed significantly higher clinical remission and endoscopic response on Skyrizi vs placebo at week 12, with FORTIFY confirming durability through week 52. No head-to-head trial has directly compared Cimzia with Skyrizi in Crohn's. Indirect comparisons suggest Skyrizi offers stronger endoscopic response rates, while Cimzia offers earlier onset.

Onset of Action

Cimzia produces meaningful Crohn's response by week 6 based on PRECISE. Skyrizi's Crohn's onset is slightly slower, with meaningful response typically by week 12 based on ADVANCE. For Crohn's patients with severe, active symptoms who need rapid control, Cimzia's faster onset is often preferred. For patients in less acute states or those weighing long-term administration and safety, Skyrizi's response trajectory is generally acceptable given the other advantages.

Safety and Infection Risk

Cimzia carries anti-TNF class risks including serious infections, reactivation of latent TB or hepatitis B, and a small increase in lymphoma risk. Skyrizi's Crohn's safety data from ADVANCE, MOTIVATE, and FORTIFY has been favorable, consistent with its broader psoriasis experience. Long-term data for IL-23 p19 biologics consistently shows lower rates of serious systemic infection than anti-TNFs. For cimzia vs skyrizi side effects in patients with infection concerns, cancer history, or comorbidities, Skyrizi's narrower mechanism often looks more favorable. Both drugs require TB and hepatitis B screening before starting.

Administration and Dosing

Cimzia for Crohn's uses 400 mg SC at weeks 0, 2, and 4 for induction, then 400 mg every 4 weeks for maintenance, per UCB's prescribing information. Cimzia is all-SC throughout. Skyrizi for Crohn's uses IV induction at weeks 0, 4, and 8 (600 mg per infusion), followed by subcutaneous maintenance of 360 mg every 8 weeks via a prefilled cartridge and on-body injector, per AbbVie's prescribing information. For Crohn's patients comparing administration, Cimzia is fully SC, while Skyrizi requires IV induction before transitioning to SC maintenance. Skyrizi's every-8-week maintenance cadence is less frequent than Cimzia's every-4-week schedule.

Fistulizing Crohn's

For fistulizing Crohn's complications, anti-TNFs including Cimzia have historically had the strongest trial data. Skyrizi's fistulizing data is emerging from post-marketing experience but is less extensive than anti-TNF class data. For Crohn's patients with significant perianal disease, the choice between Cimzia and Skyrizi often includes consideration of this factor.

Pregnancy Considerations

Cimzia's lack of an Fc region minimizes active placental transfer during pregnancy, resulting in very low infant drug levels at birth. Skyrizi undergoes active placental transfer via FcRn like other IgG biologics. For Crohn's patients who are pregnant or planning pregnancy and need to maintain biologic therapy through delivery, Cimzia's pregnancy profile is often preferred.

Anti-TNF Experienced Patients

For patients who have failed or lost response to a prior anti-TNF, a mechanism switch to Skyrizi is supported by MOTIVATE data. Cycling within the anti-TNF class (for example, to Cimzia from another anti-TNF) typically delivers lower response rates than changing mechanism classes. For Crohn's patients with prior anti-TNF exposure, Skyrizi often has better expected response.

Choosing With Your GI

For a Crohn's patient deciding between Cimzia and Skyrizi, Cimzia tends to win on faster onset, fully SC administration throughout, pregnancy considerations, and fistulizing disease outcomes. Skyrizi tends to win on long-term safety, less frequent SC maintenance (every 8 weeks vs every 4 weeks), stronger endoscopic outcomes, and performance in anti-TNF experienced patients. Ask your GI how response will be measured after induction, what to do if symptoms persist, and how your insurance handles each option. A log of stool frequency, urgency, abdominal pain, and any new symptoms between visits gives your care team the data to recognize early loss of response before a full flare returns.